Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) Research & Development (2023 - 2025)

Rallybio's Research & Development history spans 3 years, with the latest figure at $4.1 million for Q3 2025.

  • For Q3 2025, Research & Development fell 49.72% year-over-year to $4.1 million; the TTM value through Sep 2025 reached $23.3 million, down 53.39%, while the annual FY2024 figure was $41.5 million, 22.48% down from the prior year.
  • Research & Development for Q3 2025 was $4.1 million at Rallybio, down from $6.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $15.9 million in Q4 2023 and bottomed at $4.1 million in Q3 2025.
  • The 3-year median for Research & Development is $11.2 million (2023), against an average of $10.1 million.
  • The largest annual shift saw Research & Development grew 15.48% in 2024 before it crashed 55.74% in 2025.
  • A 3-year view of Research & Development shows it stood at $15.9 million in 2023, then plummeted by 53.62% to $7.4 million in 2024, then tumbled by 43.9% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for RLYB's Research & Development are $4.1 million (Q3 2025), $6.1 million (Q2 2025), and $5.7 million (Q1 2025).